Dangerous Drugs Archives | TorHoerman Law

Question 1

Can Dupixent make cutaneous T-cell lymphoma harder to recognize?

Accepted Answer

Yes, that is one of the central concerns raised in current medical literature and Dupixent lawsuits.

Dupilumab may mask early signs of CTCL due to its anti-inflammatory effects, leading to delayed diagnosis.

Cutaneous T-cell lymphoma can look very similar to severe eczema in its early stages, with red, itchy, scaly patches or plaques that do not immediately appear cancerous.

In some reported cases, patients were treated for presumed atopic dermatitis with Dupixent before repeat biopsies or additional testing later identified CTCL.

That does not prove Dupixent caused the cancer, but it does raise concerns that ongoing treatment for “eczema” may delay the correct diagnosis in some patients.

This issue is one reason Dupixent litigation often focuses on failure-to-warn allegations and the need for closer evaluation of persistent or changing skin disease.

Question 2

Can I sue if I developed cutaneous T-cell lymphoma after using Dupixent?

Accepted Answer

Possibly.

People who were diagnosed with cutaneous T-cell lymphoma after using Dupixent may have grounds to pursue a lawsuit, especially if the medical record shows the drug was prescribed before the cancer was identified and the disease may have been misdiagnosed or diagnosed later than it should have been.

These cases usually focus on failure-to-warn and product liability allegations against the manufacturers.

Patients diagnosed with cutaneous T-cell lymphoma after using Dupixent may be eligible for compensation for medical expenses and damages.

A lawyer can review your diagnosis, treatment timeline, biopsy history, and other records to determine whether your case may qualify.

Question 3

Why is the FDA watching Dupixent for possible lymphoma risk?

Accepted Answer

The FDA has not said that Dupixent causes lymphoma, but it has publicly flagged cutaneous T-cell lymphoma, or CTCL, as a safety signal that warrants review.

Dupixent has been placed on a kind of FDA “watch list” through the agency’s FAERS potential-signals reporting process due to potential signals of serious risk related to CTCL.

In the FDA’s October–December 2024 FAERS quarterly report, the agency listed “Dupixent (dupilumab) injection – Cutaneous T-cell lymphoma” and stated that it was evaluating the need for regulatory action.

The current FDA-approved Dupixent label still does not include a lymphoma-specific warning, which means the agency is monitoring the issue but has not reached a final conclusion or required a cancer warning.

What that FDA monitoring status means:

It is a signal, not a final finding: FDA says inclusion on the FAERS potential-signals list does not mean the agency has concluded the drug has the listed risk.
The agency is reviewing CTCL specifically: The signal identified for Dupixent is cutaneous T-cell lymphoma, not a broad confirmed warning about all cancers.
FDA can take different next steps: Signal review can lead to more monitoring, label changes, other regulatory action, or no action, depending on what the review shows.
The current label has not changed to add a cancer warning: As of the latest accessible prescribing information, Dupixent’s U.S. label still does not include a lymphoma warning.

Question 4

What are the symptoms of T-cell lymphoma that can be mistaken for eczema?

Accepted Answer

Cutaneous T-cell lymphoma often begins with itchy, red, scaly patches or plaques that can look a lot like eczema, dermatitis, or psoriasis.

As it progresses, the skin may develop thicker raised plaques, nodules, tumors, widespread redness, or sores that break open, and some people also notice hair loss in affected areas.

More concerning symptoms can include swollen lymph nodes, fevers, night sweats, or unexplained weight loss, especially when a long-standing “eczema” rash keeps changing or fails treatment.

CTCL does not always show up clearly on the first biopsy, which is one reason persistent or unusual skin disease may need repeat testing and specialist review.

If symptoms keep worsening instead of behaving like ordinary eczema, doctors may need to consider lymphoma in the differential diagnosis.

Question 5

What medical records can help support a Dupixent lymphoma claim?

Accepted Answer

Medical records are often the foundation of a Dupixent lymphoma claim because they show when the drug was prescribed, how the skin disease changed, and when lymphoma was finally diagnosed.

In many of these cases, the timeline matters as much as the diagnosis itself, especially when the record shows years of treatment for presumed eczema before CTCL or another T-cell lymphoma was confirmed.

Lawyers and medical experts usually look for documentation that helps connect Dupixent use, worsening symptoms, repeat biopsy history, and cancer progression.

Records that may help support a Dupixent lymphoma claim include:

Dermatology records showing the original diagnosis, such as atopic dermatitis or severe eczema
Pharmacy and prescribing records showing when Dupixent was started, how long it was used, and the dosing history
Biopsy reports and pathology findings confirming CTCL, mycosis fungoides, Sézary syndrome, or another lymphoma
Clinical notes describing worsening rash, plaques, tumors, or other skin changes during treatment
Records of repeat biopsies, clonality testing, blood testing, or referral to oncology or hematology
Imaging studies, such as CT or PET scans, used to stage the lymphoma
Hospital and oncology records showing chemotherapy, radiation, immunotherapy, or other treatment
Photographs or patient documentation showing visible skin progression over time
Death certificates, hospice records, or autopsy findings in wrongful death cases

Illinois

Missouri

Dangerous Drugs

Dangerous Drugs

Edwardsville Office

Chicago Office

St. Louis Office

Naperville Office

Clayton Office